Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...
Nephrotic Syndrome II : Assessment and Medical Management01:26

Nephrotic Syndrome II : Assessment and Medical Management

IntroductionNephrotic syndrome is a kidney disorder marked by excessive protein loss in the urine, leading to various systemic complications. This condition often results from damage to the glomeruli—the kidney's filtering units—causing proteinuria, low blood protein levels, and fluid retention. Understanding the assessment, diagnosis, and management of nephrotic syndrome is essential for effective treatment and prevention of further kidney damage.AssessmentPatient History: Document any history...
Pre-Procedural Guidelines for Assessing Blood Pressure01:10

Pre-Procedural Guidelines for Assessing Blood Pressure

Accurate blood pressure assessment is crucial for diagnosing and managing various health conditions. To ensure the reliability of these measurements, healthcare professionals must adhere to standardized pre-procedural guidelines. These guidelines enhance patient safety and improve the overall quality of healthcare. The following steps are essential for obtaining accurate and consistent blood pressure readings, from using the appropriate tools to ensuring effective communication with the patient.
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation01:21

Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
Assessment of blood pressure in brachial artery(two-step method)01:23

Assessment of blood pressure in brachial artery(two-step method)

Measuring blood pressure is a fundamental skill in healthcare that aids in diagnosing and monitoring hypertension and other cardiovascular conditions. An aneroid sphygmomanometer, commonly used in clinical settings, offers a manual and precise method for blood pressure measurement. The technique for using this instrument involves specific steps that must be carefully executed to ensure accuracy. The following detailed description outlines a two-step technique for assessing blood pressure using...
Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis01:25

Type II Diabetes Mellitus III: Clinical Manifestations and Diagnosis

Type 2 diabetes mellitus develops gradually and is often asymptomatic in early stages.Clinical ManifestationsWhen symptoms appear, they include fatigue, blurred vision, pruritus, delayed wound healing, and recurrent infections, particularly candidal infections. Peripheral neuropathy may present as numbness or tingling in the extremities. Classic hyperglycemia symptoms—polyuria, polydipsia, and polyphagia—are less common. Most patients are overweight and frequently have associated hypertension...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cytokine Profiles in Patients with Chronic Kidney Disease and Low Sexual Function.

American journal of physiology. Renal physiology·2026
Same author

Impact of Prior Adverse Pregnancy Outcome on Kidney Structure and Function in Kidney Donors.

Kidney360·2026
Same author

Rural Health and Health Disparities in Hypertension Management: A Scientific Statement From the American Heart Association.

Hypertension (Dallas, Tex. : 1979)·2026
Same author

p21-senescent cells drive pancreatic islet dysfunction through targetable paracrine signaling in type 2 diabetes.

JCI insight·2026
Same author

Distinct senescent β-cell senotypes differentially drive islet aging and dysfunction.

bioRxiv : the preprint server for biology·2026
Same author

A Multiregional Decentralized Clinical Trial Program to Improve Access.

JAMA network open·2026

Related Experiment Video

Updated: May 13, 2026

A Plate-based Cytotoxicity Assay for the Assessment of Rat Placental Natural Killer Cell Cytolytic Function
10:44

A Plate-based Cytotoxicity Assay for the Assessment of Rat Placental Natural Killer Cell Cytolytic Function

Published on: June 2, 2019

Method of diagnosing pre-eclampsia.

Steven J Wagner1, Vesna D Garovic

  • 1Mayo Clinic, Division of Nephrology and Hypertension, 200 First Street SW, Rochester, Minnesota 55905, USA +1 507 284 3594 ; +1 507 284 1161 ; garovic.vesna@mayo.edu.

Expert Opinion on Medical Diagnostics
|March 16, 2013
PubMed
Summary
This summary is machine-generated.

Researchers identified a novel biomarker for pre-eclampsia, a 26.6-kDa polypeptide. This marker is present in pre-eclamptic women, offering new diagnostic and therapeutic possibilities for this pregnancy disorder.

Related Experiment Videos

Last Updated: May 13, 2026

A Plate-based Cytotoxicity Assay for the Assessment of Rat Placental Natural Killer Cell Cytolytic Function
10:44

A Plate-based Cytotoxicity Assay for the Assessment of Rat Placental Natural Killer Cell Cytolytic Function

Published on: June 2, 2019

Area of Science:

  • Obstetrics and Gynecology
  • Biomarker Discovery
  • Maternal-Fetal Medicine

Background:

  • Pre-eclampsia is a serious pregnancy disorder causing significant maternal and fetal complications.
  • Current diagnostic, treatment, and prevention strategies for pre-eclampsia are limited.
  • There is a critical need for reliable biomarkers for early detection and management.

Purpose of the Study:

  • To identify and validate a novel biomarker for pre-eclampsia.
  • To explore the potential of this biomarker in diagnostic testing and therapeutic development.
  • To provide evidence for a patent application regarding a pre-eclampsia marker.

Main Methods:

  • Identification of a specific 26.6-kDa polypeptide.
  • Comparative analysis of polypeptide presence in pre-eclamptic women versus normal controls.
  • Evidence generation for a patent application.

Main Results:

  • A 26.6-kDa polypeptide was identified as a potential marker for pre-eclampsia.
  • This polypeptide is present in women with pre-eclampsia.
  • The polypeptide is absent in women with normal pregnancies.

Conclusions:

  • The identified 26.6-kDa polypeptide serves as a promising biomarker for pre-eclampsia.
  • This discovery opens avenues for developing new diagnostic laboratory tests.
  • Potential for risk stratification and novel therapeutic interventions for pre-eclampsia exists.